Active Biotech AB (publ) announced that Dr. Erik Vahtola, MD, PhD, has been appointed Chief Medical Officer, effective January 1, 2022. He will join the executive management team and be responsible for the development of the company´s clinical project portfolio within solid and hematological cancers, and inflammatory eye disorders.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.557 SEK | +8.16% | +9.86% | +22.02% |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+22.02% | 17.67M | |
+9.83% | 115B | |
+10.80% | 105B | |
-10.84% | 22.71B | |
-1.83% | 21.83B | |
-10.86% | 18.18B | |
-41.92% | 16.52B | |
-15.11% | 16.01B | |
+6.62% | 14.14B | |
+17.53% | 10.71B |
- Stock Market
- Equities
- ACTI Stock
- News Active Biotech AB
- Active Biotech AB Appoints Erik Vahtola as Chief Medical Officer